Neoadjuvant chemotherapy for localized pancreatic cancer: Too little or too long?

Annals of Surgical Oncology

Volumn 21, Issue 5, 2014, Pages 1508-1509

  White, Rebekah R ^a   Evans, Douglas B ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; EDITORIAL; HUMAN; LAPAROSCOPY; MICROMETASTASIS; MORBIDITY; PANCREAS CANCER; PANCREAS RESECTION; PROSPECTIVE STUDY; SELECTION BIAS; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT THERAPY; PANCREATIC NEOPLASMS; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84898901602     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3490-3     Document Type: Editorial

References (4)

1. Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: A meta-analysis of prospective studies. Ann Surg Oncol. 2012;19:1644-62.
2. Cho SW, Tzeng CW, Johnston WC, Cassera MA, Newell PH, Hammill CW, et al. Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: Analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). HPB (Oxford). 2013 [Epub ahead of print].
3. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al., Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749-56.
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-703.